At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 190 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis
In Brief
A Phase 3 clinical trial evaluating Placebo and Zoledronic acid for Post-menopausal Osteoporosis. Completed, enrolled 190 participants across 57 sites in 18 countries.
Detailed Summary
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-menopausal Osteoporosis
CountriesArgentina, Australia, Belgium, Canada, Colombia, Finland, France, Germany, Hong Kong, Hungary, Italy, New Zealand, Norway, Poland, Sweden, Switzerland, Thailand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJul 2008
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 21, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.9 years ago
Interventions
Placebodrug
Zoledronic aciddrug